A PYMNTS Company

Eleventh Circuit Rejects the Strength of a Patent as a Criterion for the Legality of Reverse-Payment Settlements

BY | June 27, 2012

Jodi Lucena-Pichardo, William Rooney, Jun 27, 2012 The Eleventh Circuit’s recent decision in Federal Trade Commission v. Watson Pharmaceuticals, Inc. (the “AndroGel” decision) addresses the latest challenge to reverse-payment settlements. The…

Jodi Lucena-Pichardo, William Rooney, Jun 27, 2012

The Eleventh Circuit’s recent decision in Federal Trade Commission v. Watson Pharmaceuticals, Inc. (the “AndroGel” decision) addresses the latest challenge to reverse-payment settlements. The Eleventh Circuit rejected the Federal Trade Commission’s position that the lawfulness of a reverse-payment settlement depends on the perceived strength or weakness of the patent and concluded that a patent, unless previously invalid

...
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 44.211.117.197

Please verify email or join us to access premium content!